Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated Pulmonary Hypertension)

ABSTRACT

Recent years have witnessed a significant increase in the knowledge about the pathophysiology of pulmonary arterial hypertension (PAH) and the availability of multiple drugs specifically aimed at pulmonary circulation. Although most of this is related to the idiopathic form of PAH, this development has also turned attention to other forms of pulmonary hypertension such as schistosomiasis-associated PAH (Sch-PAH), portopulmonary hypertension (POPH), and hemolysis-associated pulmonary hypertension. The importance of these different forms of pulmonary hypertension spans their epidemiology and the multiple pathophysiological mechanisms associated with their development and complications. Taken together, Sch-PAH and hemolysis-associated pulmonary hypertension may represent the most prevalent forms of PAH worldwide. Portopulmonary hypertension is particularly important if the morbidity and mortality that it adds to patients with liver disease is considered. Although clear progress has been reached in these various forms of PAH, there are many different aspects yet to be addressed that may contribute to the basis of specific treatment applied to these subgroups of patients.

Schistosomiasis - hemolysis-associated pulmonary hypertension - portopulmonary hypertension

REFERENCES

• 1 Ross A G, Bartley P B, Sleigh A C et al.. Schistosomiasis.  N Engl J Med. 2002;  346 1212-1220
• 2 Vennervald B J, Dunne D W. Morbidity in schistosomiasis: an update.  Curr Opin Infect Dis. 2004;  17 439-447
• 3 Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control.  Acta Trop. 2000;  77 41-51
• 4 Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis.  Lancet. 2006;  368 1106-1118
• 5 Prata A. Mansonic schistosomiasis. In: Veronesi R, Foccacia R, Dietze R Doenças Infecciosas e Parasitárias. 8th ed. São Paulo; Guanabara Koogan 1991: 838-855
• 6 Pedroso E R. Lung changes associated with schistosomiasis mansoni [in Portuguese].  Mem Inst Oswaldo Cruz. 1989;  84(Suppl 1) 46-57
• 7 Conceição M J, Borges-Pereira J, Coura J R. A thirty years follow-up study on Schistosomiasis mansoni in a community of Minas Gerais, Brazil.  Mem Inst Oswaldo Cruz. 2007;  102 1007-1009
• 8 Lapa M S, Ferreira E V, Jardim C, Martins BdoC, Arakaki J S, Souza R. Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo [in Portuguese].  Rev Assoc Med Bras. 2006;  52 139-143
• 9 Lapa M, Dias B, Jardim C et al.. Cardiopulmonary manifestations of hepatosplenic schistosomiasis.  Circulation. 2009;  119 1518-1523
• 10 Shaw A P, Ghareeb A. The pathogenesis of pulmonary schistosomiasis in Egypt with special reference to Ayerza's disease.  J Pathol Bacteriol. 1938;  46 401-424
• 11 Magalhaes Filho A. Pulmonary lesions in mice experimentally infected with Schistosoma mansoni.  Am J Trop Med Hyg. 1959;  8 527-535
• 12 Chaves E. Pulmonary schistosomiasis arteritis; morphological study of 54 cases with special reference to hypersensitivity reactions [in Portuguese].  Hospital (Rio J). 1964;  66 1335-1346
• 13 Chaves E. Plexiform lesions in chronic cor pulmonale in schistosomiasis [in Portuguese].  Hospital (Rio J). 1965;  68 635-645
• 14 Chaves E. Pathology of pulmonary endarteritis obliterans in Manson's schistosomiasis [in Portuguese].  An Inst Med Trop (Lisb). 1965;  22 171-177
• 15 Chaves E. The pathology of the arterial pulmonary vasculature in Manson's schistosomiasis.  Dis Chest. 1966;  50 72-77
• 16 de Cavalcanti I L, Tompson G, Barbosa F S, de SOUZA . Pulmonary hypertension in schistosomiasis.  Br Heart J. 1962;  24 363-371
• 17 Pozzan G, Souza R, Jardim C et al.. Histopathological features of pulmonary vascular disease in chronic Schistosomia mansoni infection are not different from those in idiopathic pulmonary hypertension [abstract].  Am J Respir Crit Care Med. 2008;  177 A443
• 18 Pereira Jr G A, Bestetti R B, Leite M P et al.. Portopulmonary hypertension syndrome in schistosomiasis mansoni.  Trans R Soc Trop Med Hyg. 2002;  96 427-428
• 19 Schwartz E. Pulmonary schistosomiasis.  Clin Chest Med. 2002;  23 433-443
• 20 Zhou Y G, Yang Z, Li D J. The experimental study on pathological changes of pulmonary tissues in portal hypertensive rabbits with schistosomal cirrhosis [in Chinese].  Zhonghua Wai Ke Za Zhi. 2005;  43 587-590
• 21 Simonneau G, Galiè N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
• 22 Figueiredo C, Souza R, Ota J S, Moises V, Barone R, Rocha M. Pulmonary hypertension in schistosomiasis: a chest CT study [abstract].  Am J Respir Crit Care Med. 2004;  169 A174
• 23 Hatz C, Jenkins J M, Ali Q M, Abdel-Wahab M F, Cerri G G, Tanner M. A review of the literature on the use of ultrasonography in schistosomiasis with special reference to its use in field studies, II: Schistosoma mansoni.  Acta Trop. 1992;  51 15-28
• 24 Igreja R P, Matos J A, Gonçalves M M, Barreto M M, Peralta J M. Schistosoma mansoni-related morbidity in a low-prevalence area of Brazil: a comparison between egg excretors and seropositive non-excretors.  Ann Trop Med Parasitol. 2007;  101 575-584
• 25 Galiè N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 26 Loureiro R, Mendes A, Bandeira A, Cartaxo H, Sa D. Oral sildenafil improves functional status and cardiopulmonary hemodynamics in patients with severe pulmonary hypertension secondary to chronic pulmonary schistosomiasis: a cardiac magnetic resonance study. American Heart Association International Meeting November 7–10, 2004 New Orleans, LA; 2569
• 27 Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies.  Acta Trop. 2000;  77 111-131
• 28 Bourée P, Piveteau J, Gerbal J L, Halpen G. Pulmonary arterial hypertension due to bilharziasis. Apropos of a case due to Schistosoma haematobium having been cured by praziquantel [in French].  Bull Soc Pathol Exot. 1990;  83 66-71
• 29 Mantz Jr F A, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale.  AMA Arch Pathol. 1951;  52 91-97
• 30 Krowka M J. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas.  Hepatology. 1997;  25 1282-1284
• 31 Rodríguez-Roisin R, Krowka M J. Hepatopulmonary syndrome—a liver-induced lung vascular disorder.  N Engl J Med. 2008;  358 2378-2387
• 32 Rodríguez-Roisin R, Krowka M J, Hervé P, Fallon M B. ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee . Pulmonary-Hepatic vascular Disorders (PHD).  Eur Respir J. 2004;  24 861-880
• 33 Hervé P, Lebrec D, Brenot F et al.. Pulmonary vascular disorders in portal hypertension.  Eur Respir J. 1998;  11 1153-1166
• 34 Hadengue A, Benhayoun M K, Lebrec D, Benhamou J P. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics.  Gastroenterology. 1991;  100 520-528
• 35 Golbin J M, Krowka M J. Portopulmonary hypertension.  Clin Chest Med. 2007;  28 203-218, ix
• 36 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 37 Porres-Aguilar M, Zuckerman M J, Figueroa-Casas J B, Krowka M J. Portopulmonary hypertension: state of the art.  Ann Hepatol. 2008;  7 321-330
• 38 Mandell M S, Groves B M. Pulmonary hypertension in chronic liver disease.  Clin Chest Med. 1996;  17 17-33
• 39 Lee S D, Shroyer K R, Markham N E, Cool C D, Voelkel N F, Tuder R M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.  J Clin Invest. 1998;  101 927-934
• 40 Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.  N Engl J Med. 1992;  327 1774-1778
• 41 Wagenvoort C A, Mulder P G. Thrombotic lesions in primary plexogenic arteriopathy: similar pathogenesis or complication?.  Chest. 1993;  103 844-849
• 42 Castro M, Krowka M J, Schroeder D R et al.. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.  Mayo Clin Proc. 1996;  71 543-551
• 43 Colle I O, Moreau R, Godinho E et al.. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.  Hepatology. 2003;  37 401-409
• 44 Ramsay M A, Simpson B R, Nguyen A T, Ramsay K J, East C, Klintmalm G B. Severe pulmonary hypertension in liver transplant candidates.  Liver Transpl Surg. 1997;  3 494-500
• 45 Humbert M, Sitbon O, Chaouat A et al.. Pulmonary arterial hypertension in France: results from a national registry.  Am J Respir Crit Care Med. 2006;  173 1023-1030
• 46 Thenappan T, Shah S J, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006.  Eur Respir J. 2007;  30 1103-1110
• 47 Le Pavec J, Souza R, Herve P et al.. Portopulmonary hypertension: survival and prognostic factors.  Am J Respir Crit Care Med. 2008;  178 637-643
• 48 Budhiraja R, Hassoun P M. Portopulmonary hypertension: a tale of two circulations.  Chest. 2003;  123 562-576
• 49 Krowka M J, Swanson K L, Frantz R P, McGoon M D, Wiesner R H. Portopulmonary hypertension: results from a 10-year screening algorithm.  Hepatology. 2006;  44 1502-1510
• 50 De Wolf A M, Scott V L, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation.  Anesthesiology. 1993;  78 213-214
• 51 Krowka M J, Mandell M S, Ramsay M A et al.. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.  Liver Transpl. 2004;  10 174-182
• 52 Krowka M J, Frantz R P, McGoon M D, Severson C, Plevak D J, Wiesner R H. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension.  Hepatology. 1999;  30 641-648
• 53 Hoeper M M, Halank M, Marx C et al.. Bosentan therapy for portopulmonary hypertension.  Eur Respir J. 2005;  25 502-508
• 54 Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation.  Liver Transpl. 2004;  10 945-950
• 55 Hoeper M M, Seyfarth H J, Hoeffken G et al.. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.  Eur Respir J. 2007;  30 1096-1102
• 56 Barth F, Gerber P J, Reichen J, Dufour J F, Nicod L P. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.  Eur J Gastroenterol Hepatol. 2006;  18 1117-1119
• 57 Gough M S, White R J. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension.  Liver Transpl. 2009;  15 30-36
• 58 Swanson K L, Wiesner R H, Nyberg S L, Rosen C B, Krowka M J. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups.  Am J Transplant. 2008;  8 2445-2453
• 59 Findlay J Y, Plevak D J, Krowka M J, Sack E M, Porayko M K. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.  Liver Transpl Surg. 1999;  5 362-365
• 60 Gladwin M T, Vichinsky E. Pulmonary complications of sickle cell disease.  N Engl J Med. 2008;  359 2254-2265
• 61 Olivieri N F. The beta-thalassemias.  N Engl J Med. 1999;  341 99-109
• 62 Bunn H F. Pathogenesis and treatment of sickle cell disease.  N Engl J Med. 1997;  337 762-769
• 63 Gladwin M T, Schechter A N, Ognibene F P et al.. Divergent nitric oxide bioavailability in men and women with sickle cell disease.  Circulation. 2003;  107 271-278
• 64 Haque A K, Gokhale S, Rampy B A, Adegboyega P, Duarte A, Saldana M J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases.  Hum Pathol. 2002;  33 1037-1043
• 65 Kato G J, McGowan V, Machado R F et al.. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.  Blood. 2006;  107 2279-2285
• 66 Anthi A, Machado R F, Jison M L et al.. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.  Am J Respir Crit Care Med. 2007;  175 1272-1279
• 67 Castro O, Hoque M, Brown B D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.  Blood. 2003;  101 1257-1261
• 68 McLaughlin V V, Rich S. Pulmonary hypertension.  Curr Probl Cardiol. 2004;  29 575-634
• 69 Sachdev V, Machado R F, Shizukuda Y et al.. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease.  J Am Coll Cardiol. 2007;  49 472-479
• 70 Gladwin M T, Sachdev V, Jison M L et al.. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.  N Engl J Med. 2004;  350 886-895
• 71 Steinberg M H. Management of sickle cell disease.  N Engl J Med. 1999;  340 1021-1030
• 72 Morris C R, Morris Jr S M, Hagar W et al.. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?.  Am J Respir Crit Care Med. 2003;  168 63-69